Breakthrough in Neurodegenerative Disease Research: Targacept's Groundbreaking Findings

Strategic Insights -

Research conducted by Targacept and the Medical College of Georgia has made significant strides in understanding the mechanisms of cell death in neurodegenerative diseases such as Alzheimer's and Parkinson's disease. The study, published in The Journal of Neuroscience, reveals that the enzyme SHP-1 plays a crucial role in blocking a key cellular pathway triggered by the activation of the alpha-7 neuronal nicotinic receptor, which protects against the negative effects of beta-amyloid. These findings offer new insights into the treatment of neurodegenerative diseases, with potential therapeutic applications in slowing disease progression.

Key Takeaways:

  • Researchers at Targacept and the Medical College of Georgia have identified SHP-1 as a key enzyme implicated in cell death, which contributes to the progression of neurodegenerative diseases such as Alzheimer's and Parkinson's disease.
  • The alpha-7 neuronal nicotinic receptor has been found to trigger a cellular pathway that protects against the negative effects of beta-amyloid.
  • Activating receptors involved in cell survival, while minimizing effects resulting in cell death, may have significant therapeutic advantages in the treatment of neurodegenerative diseases.
  • Targacept is a central nervous system-focused biopharmaceutical company developing a new class of drugs to treat a broad spectrum of diseases, including memory disorders, attention deficit hyperactivity disorder, ulcerative colitis, pain, and Alzheimer's disease.
  • Merouane Bencherif, MD, PhD, Targacept's vice president, preclinical research, emphasizes the importance of these findings in advancing the understanding of cell death mechanisms in neurodegenerative diseases.

Statistics:

  • 2003: The year in which Targacept announced research results identifying SHP-1 as a key enzyme implicated in cell death.
  • The study was reported in The Journal of Neuroscience.
  • Beta-amyloid is present in the brains of Alzheimer patients, contributing to the progression of the disease.
  • Activation of the enzyme SHP-1 blocks the cellular pathway triggered by the alpha-7 neuronal nicotinic receptor.
  • The protein beta-amyloid induces neuronal cell death, contributing to the deterioration of a patient's quality of life.

Sources:

  • NewsRx.com & NewsRx.net
  • The Journal of Neuroscience
  • Targacept, Inc. press release (2003 DEC 29)
  • Health & Medicine Week editors from staff and other reports